Tirofiban Blocks Platelet Adhesion to Fibrin with Minimal Perturbation of GpIIb/IIIa Structure

Roy R. Hantgan; Mary C. Stahle; Gray W. Jerome; Chandrasekaran Nagaswami; John W. Weisel

doi:10.1055/s-0037-1613104

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2002; 87(05): 910-917
DOI: 10.1055/s-0037-1613104

Review Article

Schattauer GmbH

Tirofiban Blocks Platelet Adhesion to Fibrin with Minimal Perturbation of GpIIb/IIIa Structure

Roy R. Hantgan

¹Department of Biochemistry, Winston-Salem, NC

,

Mary C. Stahle

¹Department of Biochemistry, Winston-Salem, NC

,

Gray W. Jerome

²Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, NC

,

Chandrasekaran Nagaswami

³Department of Cell and Developmental Biology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA

,

John W. Weisel

³Department of Cell and Developmental Biology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA

› Institutsangaben

Abstract

Summary

A biophysical approach tested the hypothesis that tirofiban, like eptifibatide, perturbs GpIIb/IIIa structure. Tirofiban bound tightly to platelet GpIIb/IIIa (EC₅₀ ∼ 24 nmol/L) and effectively inhibited platelet aggregation (IC₅₀ ∼ 37 nmol/L) but blocked platelet adhesion to clotted fibrin only at much higher doses (IC₅₀ ∼ 580 nmol/L). Electrophoretic analyses demonstrated that tirofiban protected GpIIb/IIIa from SDSinduced subunit dissociation. However, saturating tirofiban concentrations had little or no effect on GpIIb/IIIa secondary or tertiary structure, as determined by circular dichroic spectroscopy, dynamic light scattering, and sedimentation velocity measurements performed with purified receptors in octyl glucoside. Moderate dose-dependent effects on GpIIb/IIIa quaternary structure were detected by sedimentation equilibrium. Transmission electron microscopy showed minimal tirofiban-induced receptor activation or oligomerization. Thus, even at the increased concentrations needed to block platelet:fibrin adhesive interactions, tirofiban exhibited only limited effects on GpIIb/IIIa conformation and clustering. Our results provide new insights into the mechanisms and potential prothrombotic complications of integrin antagonists.

Keywords

GpIIb/IIIa - integrin α_IIbβ₃ - integrin antagonist - fibrin - structure

Volltext

Referenzen

References
1 Cook JJ, Bednar B, Lynch JJ, Gould RJ, Egbertson MS, Halczenko W, Duggan ME, Hartman GD, Lo MW, Murphy GM, Deckelbaum LI, Sax FL, Barr E. Tirofiban (Aggrastat®). Cardiovascular Drug Reviews 1999; 17: 199-224.
2 Theroux P. Tirofiban. Drugs Of Today 1999; 35: 59-73.
3 Hanrath P, Vom Dahl J, Paulus W, Heyndrickx G, Sosa JA, Muller D, King SB, Resar JR, Herzog W, Silver MT, Green B, Lewis HS, Schultheiss HP, Meier B, Cohen D, Jang IK, Losordo DW, Palabrica T, Piana R, Monrad ES, Shani J, Rousseau MF, Col J, Corbelli J. Effects of platelet glycoprotein IIb/IIIa blockade with Tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997; 96: 1445-53.
4 The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998; 338: 1488-97.
5 The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998; 338: 1498-505.
6 Tcheng JE. Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment. Am Heart J 2000; 139 (Pt2); S38-45.
7 Chew DP, Moliterno DJ. A critical appraisal of platelet glycoprotein IIb/IIIa inhibition. J Am Coll Cardiol 2000; 36: 2028-35.
8 Bhatt DL, Topol EJ. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. JAMA 2000; 284: 1549-58.
9 Chew DP, Bhatt DL, Sapp S, Topol EJ. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists – A meta-analysis of phase III multicenter randomized trials. Circulation 2001; 103: 201-6.
10 Frelinger AL, Du XP, Plow EF, Ginsberg MH. Monoclonal-Antibodies To Ligand-Occupied Conformers Of Integrin α _IIb β ₃ (Glycoprotein-IIb-IIIa) Alter Receptor Affinity, Specificity, And Function. J Biol Chem 1991; 266: 17106-11.
11 McLane MA, Marcinkiewicz C, Niewiarowski S. Disintegrins induce expression of ligand-induced binding-sites on platelets and chinesehamster ovary cells transfected with α _IIb β ₃ which correlates with disintegrin binding-affinity to resting platelets. Thromb Haemost 1995; 73: 1194.
12 Honda S, Tomiyama Y, Aoki T, Shiraga M, Kurata Y, Seki J, Matsuzawa Y. Association between ligand-induced conformational changes of integrin α _IIb β ₃ and α _IIb β ₃ mediated intracellular Ca2+ signaling. Blood 1998; 92: 3675-83.
13 Jennings LK, Haga JH, Slack SM. Differential expression of a ligand induced binding site (LIBS) by GPIIb-IIIa ligand recognition peptides and parenteral antagonists. Thromb Haemost 2000; 84: 1095-102.
14 Peter K, Schwarz M, Ylanne J, Kohler B, Moser M, Nordt T, Salbach P, Kubler W, Bode C. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa α _IIb β ₃ inhibitors. Blood 1998; 92: 3240-9.
15 Frelinger AL, Furman MI, Krueger LA, Barnard MR, Michelson AD. Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation. Circulation 2001; 104: 1374-9.
16 Hantgan RR, Paumi C, Rocco M, Weisel JW. Effects of ligand-mimetic peptides Arg-Gly-Asp-X (X=Phe, Trp, Ser) on α _IIb β ₃ integrin conformation and oligomerization. Biochemistry 1999; 38: 14461-74.
17 Hantgan RR, Rocco M, Nataswami C, Weisel JW. Binding of a FibrinogenMimetic Stabilizes Integrin α _IIb β ₃’s Open Conformation. Protein Sci 2001; 10: 1614-26.
18 Hantgan RR. A study of the kinetics of ADP-triggered platelet shape change. Blood 1984; 64: 896-906.
19 Quinn M, Deering A, Stewart M, Cox D, Foley B, Fitzgerald D. Quantifying GPIIb/IIIa receptor binding using 2 monoclonal antibodies – Discriminating abciximab and small molecular weight antagonists. Circulation 1999; 99: 2231-8.
20 Bellavite P, Andrioli G, Guzzo P, Arigliano P, Chirumbolo S, Manzato F, Santonastaso C. A colorimetric method for the measurement of platelet adhesion in microtiter plates. Anal Biochem 1994; 216: 444-50.
21 Hantgan RR, Taylor RG, Lewis JC. Platelets interact with fibrin only after activation. Blood 1985; 65: 1299-311.
22 Hantgan RR, Jerome WG, Hursting MJ. No effect of clot age or thrombolysis on argatroban’s inhibition of thrombin. Blood 1998; 92: 2064-74.
23 Hantgan RR, Braaten JV, Rocco M. Dynamic light scattering studies of α _IIb β ₃ solution conformation. Biochemistry 1993; 32: 3935-41.
24 Fowler WE, Erickson HP. Trinodular structure of fibrinogen. Confirmation by both shadowing and negative stain electron microscopy. J Mol Biol 1979; 134: 241-9.
25 Weisel JW, Stauffacher CV, Bullitt E, Cohen C. A model for fibrinogen: domains and sequence. Science 1985; 230: 1388-91.
26 Veklich YI, Gorkun OV, Medved LV, Nieuwenhuizen W, Weisel JW. Carboxyl-terminal portions of the α chains of fibrinogen and fibrin. Localization by electron microscopy and the effects of isolated αC fragments on polymerization. J Biol Chem 1993; 268: 13577-85.
27 Hantgan RR, Nichols WL, Ruggeri ZM. von Willebrand factor competes with fibrin for occupancy of GPIIb: IIIa on thrombin-stimulated platelets. Blood 1990; 75: 889-94.
28 Stafford III WF. Boundary analysis in sedimentation transport experiments: a procedure for obtaining sedimentation coefficient distributions using the time derivative of the concentration profile. Anal Biochem 1992; 203: 295-301.
29 Philo JS. An improved function for fitting sedimentation velocity data for low-molecular-weight solutes. Biophys J 1997; 72: 435-44.
30 Yphantis DA. Equilibrium ultracentrifugation of dilute solutions. Biochemistry 1964; 03: 297-317.
31 Carrell NA, Fitzgerald LA, Steiner B, Erickson HP, Phillips DR. Structure of human platelet glycoproteins IIb and IIIa as determined by electron microscopy. J Biol Chem 1985; 260: 1743-9.
32 Weisel JW, Nagaswami C, Vilaire G, Bennett JS. Examination of the platelet membrane glycoprotein IIb-IIIa complex and its interaction with fibrinogen and other ligands by electron microscopy. J Biol Chem 1992; 267: 16637-43.
33 Phillips DR, Scarborough RM. Clinical pharmacology of eptifibatide. Am J Cardiol 1997; 80: 11B-20B.
34 Scarborough RM, Naughton MA, Teng W, Rose JW, Phillips DR, Nannizzi L, Arfsten A, Campbell AM, Charo IF. Design of potent and specific integrin antagonists. Peptide antagonists with a high specificity for glycoprotein IIb-IIIa. J Biol Chem 1993; 268: 1066-73.
35 Scarborough RM, Rose JW, Naughton MA, Phillips DR, Nannizzi L, Arfsten A, Campbell AM, Charo IF. Characterization of the integrin specificities of disintegrins isolated from American pit viper venoms. J Biol Chem 1993; 268: 1058-65.
36 Minoux H, Moitessier N, Chapleur Y, Maigret B. Elucidation of a common structure of selective fibrinogen receptor antagonists. J Comput Aided Mol Des 1998; 12: 533-42.